曲美他嗪联合β受体阻滞剂对冠心病患者运动耐量、心功能及NT-proBNP水平的影响  

The influence of Trimetazidine combined with β-blockers on exercise tolerance, cardiac function and NT-pro BNP levels in patients with coronary heart disease

作　　者：岑运光[1] 李伟[1] 张旭日[1] 吴多智[1] 谢方遒[1] 崔晓燕 廖卫[2] CEN Yun-guang, LI Wei, ZHAGN Xu-ri, WU Duo-zhi, XIE Fang-qiu, CUI Xiao-yan, LIAO Wei(1. Department of the Second Medical Care, Hainan General Hospital, Haikou, 570311, China; 2. Department of Ultrasonography, Hainan General Hospital, Haikou 570311, Chin)

机构地区：[1]海南省人民医院医疗保健二区,海口570311 [2]海南省人民医院超声科,海口570311

出　　处：《中国医学前沿杂志（电子版）》2018年第6期208-211,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的分析曲美他嗪联合β受体阻滞剂对冠心病患者运动耐量、心功能及氨基末端B型利钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-pro BNP)水平的影响。方法选择2015年1月至2017年1月本院收治的100例冠心病患者为研究对象,按照随机数表法将其分为研究组和对照组,每组各50例。在常规治疗基础上,研究组患者给予曲美他嗪联合β受体阻滞剂治疗,对照组患者仅给予β受体阻滞剂治疗,治疗3个月。比较治疗前后两组患者的治疗效果、左心室舒张末期容积(left ventricular end-diastolic volume,LVEDV)、左心室收缩末期容积(left ventricular end-systolic volume,LVESV)、左心室射血分数(left ventricular ejection fraction,LVEF)和NT-pro BNP水平及运动耐量。结果研究组患者治疗有效率明显高于对照组(P<0.05)。治疗后,研究组患者达到运动终点的时间显著长于对照组,运动试验阳性例数少于对照组,最大心率小于对照组,6分钟最大步行距离大于对照组,差异均具有显著性(P_均<0.01);治疗后研究组患者的LVEDV和NT-pro BNP水平均显著低于对照组(P_均<0.05),LVEF显著高于对照组(P<0.01)。结论曲美他嗪联合β受体阻滞剂能提高冠心病的治疗效果,有效降低NT-pro BNP水平,改善患者的心功能及运动耐量。Objective To analyze the influence of Trimetazidine combined with β-blockers on exercise tolerance, cardiac function and N-terminal pro-B-type natriuretic peptide（NT-pro BNP） in patients with coronary heart disease. Method 100 patients with coronary heart disease admitted to our hospital from January 2015 to January 2017 were selected as the research objects, according to the random number table method, they were randomly divided into two groups, with 50 cases each. All patients were given the routine treatment, and research group patients were given Trimetazidine and β-blockers drug therapy, while control group patients were only given β-blockers drug therapy. The treatment lasted for 3 months. Before and after treatment, the therapeutic effect, left ventricular end-diastolic volume（LVEDV）, left ventricular end-systolic volume（LVSDV）, left ventricular ejection fraction（LVEF）, NT-pro BNP and exercise tolerance levels of two groups were compared. Result The effective rate of research group was significantly higher than control group（P〈0.05）. After treatment, the time of exercise of research group was significantly longer than that of control group, the number of positive exercise tests cases was significantly less than that of control group, and the maximum heart rate was less than that of control group, the maximum walking distance in 6 minutes was greater than that of control group（P（all） 0.01）. After treatment, LVEDV and NT-pro BNP level of research group were significantly less than those of control group（P（all）〉 0.05）, but LVEF was greater than that of control group（P〈0.01）. Conclusion Trimetazidine combined with β-blockers can improve the curative effect of coronary heart disease, effectively reduce the NT-pro BNP levels, and improve cardiac function and exercise tolerance.

关 键 词：Β受体阻滞剂 曲美他嗪 冠心病 运动耐量 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]